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INTRODUCTION
Autoimmune retinopathy (AIR) is an immune-mediated reti-
nopathy caused by circulating antiretinal antibodies. It can be 
categorized as paraneoplastic AIR including cancer-associated 
retinopathy (CAR), melanoma-associated retinopathy (MAR), 
possibly bilateral diffuse uveal melanocytic proliferation 
(BDUMP), and nonparaneoplastic AIR.1 Although the pres-
ence of antiretinal antibodies is diagnostic for AIR,2 the diag-
nosis is ultimately clinical, supported by bilateral, often asym-
metric, progressive vision loss over several weeks to months3 
and with dysfunction of photoreceptors or bipolar cells, re-
sulting in electroretinographic abnormalities.4 Here, we report 
the very first case of serologically confirmed nonparaneoplas-
tic AIR in Korea. 
CASE REPORT
A 40-year-old man visited our clinic in January 2014, having 
had progressive central vision loss in his left eye (OS) for 1 year 
and similar symptoms starting in his right eye (OD) 3 months 
prior. He did not have any significant medical history includ-
ing any autoimmune diseases and was not on any medica-
tion. Also, his ophthalmic history was unremarkable without 
history of undergoing ocular surgery or any significant ocular 
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Fig. 1. Fundus photographs, SD-OCT and visual field examination. (A) Color fundus photography of both eyes showing no apparent abnormalities. (B) Ini-
tial SD-OCT revealing blurring of ellipsoid zone at subfoveal region, more severe in the left than in the right eye. (C) Two months later, follow up SD-OCT 
demonstrating more progressed disruption of the ellipsoid zone across the entire fovea in both eyes. (D) Initial 30-2 HVF revealing central scotoma only in 
the left eye. (E) Follow up 30-2 HVF after 4 months displaying more profound cecocentral field deterioration in both eyes. SD-OCT, spectral domain-optical 
coherence tomography; HVF, humphrey visual field.
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diseases. The initial best-corrected visual acuity (BCVA) by a 
Snellen chart was 20/40 in both eyes (OU). The OS was unable 
to correctly identify any of the Ishihara color plates. A fundus 
examination was unremarkable (Fig. 1A). Spectral domain-
optical coherence tomography (SD-OCT) revealed a blurred 
ellipsoid zone at the subfoveal region in OU with more promi-
nent disruption in OS (Fig. 1B). A 30-2 Humphrey visual field 
(HVF) confirmed central field loss in OS (Fig. 1D). Full-field 
ERG showed relatively normal rod and cone responses in OD, 
but slightly decreased photopic b-waves with minimal attenu-
ation of a-waves in OS (Fig. 2A). Multifocal ERG (mfERG) 
showed slightly reduced amplitude of the inner segment ring 
in OD and decreased amplitudes and delayed latencies of all 
modalities in OS (Fig. 2B). Complete medical and oncologic 
evaluations were performed by a medical internist; however, 
no underlying abnormalities were found. RP1L1 gene analysis 
was performed to rule out occult macular dystrophy, but no 
mutation was detected. We suspected AIR and sent serum 
samples to the Oregon Health and Science University (http://
www.ohsu.edu/xd/health/services/casey-eye/diagnostic-
services/ocular-immunology-lab/services.cfm) for examina-
tion for antiretinal antibodies. A Western blot was positive for 
23-kDa protein, enolase (46-kDa), aldolase (40-kDa), 62-kDa 
and 78-kDa protein (Fig. 3A). Moderate immunohistochemi-
cal staining of some human retinal bipolar and ganglion cells 
was observed (Fig. 3B). During the 2 months of follow up, the 
patient’s visual acuity decreased progressively, with the BCVA 
declining to 20/50 in OD and 20/60 in OS. SD-OCT showed 
more extensive disruption of the ellipsoid zone and the exter-
nal limiting membrane in OU (Fig. 1C). There was no definite 
progression of mfERG abnormalities in OS, but a progression 
of delayed latency in OD with reduced amplitude in the inner 
segment ring was noted. 
Based on the diagnosis of AIR, treatment was started with 
1.0 g of high dose intravenous steroid pulse therapy for 3 days. 
Afterwards, the patient was placed on oral steroid and immu-
nosuppressive agents for 5 weeks including 60 mg predniso-
lone, 200 mg cyclosporine A, and 100 mg azathioprine. Despite 
the immunosuppressive treatment, the patient’s symptoms 
continued to worsen progressively with the BCVA decreasing 
to 20/120 in OD and 20/200 in OS from 20/40 in OU over a pe-
riod of 4 months. There was a progression of central visual field 
loss on a 30-2 HVF exam (Fig. 1E). Posterior subtenon triam-
cinolone injection was performed in OU; however, the pa-
tient’s condition failed to improve, and his visual acuity and 
visual field continued to deteriorate. The patient was subse-
quently lost to follow up, about 17 weeks after his first visit. 
DISCUSSION
AIR is an autoantibody-induced retinopathy presumably caused 
by circulating autoantibodies targeted against retinal and reti-
nal-like antigens. AIR can be classified as paraneoplastic AIR 
or nonparaneoplastic AIR. Paraneoplastic AIR results from 
the remote effects of diverse tumors and it includes CAR, 
MAR, and BDUMP. CAR revealed diffuse degeneration of 
photoreceptors in the outer retina,5 while MAR demonstra-
teed selective bipolar cell dysfunction in the inner retina,6 and 
BDUMP was characterized by diffuse uveal thickening of me-
lanocytic proliferation.7 Nonparaneoplastic AIR, the most 
common form of AIR, can share similar clinical and electro-
physiological characteristics with CAR1 but is not associated 
with an underlying malignancy. AIR patients present with 
acute or subacute bilateral visual loss. Because of its heteroge-
neous clinical features and near-normal appearance upon 
fundus examination and SD-OCT, AIR might escape diagnosis 
if it is not examined with high clinical suspicion. Full-field 
ERG could be normal in early-stage AIR; however, mfERG 
would detect the focal area of decreased amplitude.1 Various 
laboratory techniques, including immunohistochemistry, 
Western blot, and enzyme-linked immunosorbent assay, have 
been used to detect antiretinal antibodies which facilitate im-
mune-mediated retinopathy in AIR. Anti-recoverin,8 α-enolase,9 
carbonic anhydrase II,10 and rod transducin-α4 have been de-
tected in nonparaneoplastic AIR. 
AIR was suspected based on the clinical features of this 
case, including progressive visual loss over one year with nor-
mal fundus, color vision loss, central visual field defects, loss 
of the ellipsoid zone on SD-OCT, and mfERG abnormalities. 
As there was no definite evidence of tumor activity, the pa-
tient was diagnosed with presumed nonparaneoplastic AIR 
rather than CAR. This was supported by the detection of auto-
antibodies targeting various retinal antigens in serum sam-
ples. Retinopathies with hereditary, toxic, and inflammatory 
causes need to be differentiated, as they may share common 
clinical features.2 In this case, complete medical and oncolog-
ic examination including RP1L1 analysis was performed to 
rule out differential diagnosis of possible hereditary and other 
systemic causes. 
There is presently no definitive treatment of choice for AIR, 
and the evidence for therapeutic intervention is limited.1 
Long-term immunosuppression with systemic and local ste-
roids have shown favorable outcomes in some cases of AIR.6,11 
Other immunosuppressive agents8 and intravenous immuno-
globulin6 treatment have also had limited success. In our case, 
both local and systemic immunosuppression was administered 
but did not lead to visual improvement. Once the destruction of 
the retinal photoreceptors progressed, immunosuppressive in-
terventions produced very little visual improvement.
In conclusion, our report presents the first case of nonpara-
neoplastic AIR in Korea. Its clinical diagnosis was supported 
by positive Western blots for anti-retinal antibodies and by 
immunohistochemical staining of human retinal bipolar and 
ganglion cells. The early detection of anti-retinal autoantibod-
ies followed by prompt and aggressive treatment with immu-
http://dx.doi.org/10.3349/ymj.2016.57.2.527530
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Fig. 2. Results of initial examinations: full-field electroretinography (A), and multifocal electroretinography (B) or (A) Initial full field ERG of the right eye dis-
playing relatively intact responses, with slightly attenuated photopic a- and b-waves in the left eye. (B) Initial mfERG of the right eye revealing slightly re-
duced amplitude of inner segment ring and diminished amplitudes and delayed latencies of all modalities in the left eye. ERG, electroretinography; mfERG, 
multifocal ERG.
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nosuppressive agents may serve a significant role in identify-
ing and treating those who are at risk of retinal deterioration 
and blindness from AIR. 
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Fig. 3. Western blot and immunohistochemical staining results of patient’s serum. (A) The patient’s serum was positive for 23-kDa protein, enolase (46-
kDa), aldolase (40-kDa), 62-kDa and 78-kDa proteins in Western blotting. The arrows indicate positive controls (C1: a positive control for recoverin; C2: a 
positive control for enolase). (B) Moderate immunohistochemical staining of some human retinal bipolar and ganglion cells as well as photoreceptor cells 
was noted. Scale bar=50 μm.
